Pharmacovigilance assessment of ropivacaine safety using FAERS data (2004-2024).

ABSTRACT: Despite widespread clinical use of the long-acting local anesthetic ropivacaine, its population-level safety remains under-explored. This study aimed to analyze and categorize adverse events (AE) associated with ropivacaine reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS). We retrospectively extracted reports on adverse drug events (ADEs) from the FAERS database from the first quarter of 2004 to the fourth quarter of 2024. Using disproportionality analysis, including the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and the empirical Bayesian geometric mean, we assessed whether there was a significant association between ropivacaine and ADEs. The Weibull shape parameter was used to test the time to

SUBMITTER: Lai C 

PROVIDER: S-EPMC12688818 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature